ReviewCurrent atherosclerosis reports2006
C-reactive protein and cardiovascular disease: weighing the evidence.
Review in Current atherosclerosis reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 87 citations in OpenAlex.
- Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients.PloS one · 2014Trial
- Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study.Circulation. Genomic and precision medicine · 2025Review
- The role of individual and regional environment factors on levels of a cardiovascular risk predictor in middle-aged and older Chinese adults.Journal of global health · 2025Article
- The Effect of a Program to Improve Adherence to the Mediterranean Diet on Cardiometabolic Parameters in 7034 Spanish Workers.Nutrients · 2024Article
- C-reactive protein: a target for therapy to reduce inflammation.Frontiers in immunology · 2023Review
- Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Therapeutic Lowering of C-Reactive Protein.Frontiers in immunology · 2020Review
- A Control-Theoretic Model of Atherosclerosis.International journal of molecular sciences · 2019Article
- The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.Frontiers in immunology · 2018Review
- C-reactive protein and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus.International journal of ophthalmology · 2016Article
- Retinol-binding protein-4 and hs-CRP levels in patients with migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Article
- Obesity, hyperglycemia and endothelial function in inner city Bronx adolescents: a cross-sectional study.International journal of pediatric endocrinology · 2013Article
- Curbing inflammation.International journal of inflammation · 2013Article
- Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism.International journal of endocrinology · 2012Article
- The holistic perspective of chronic obstructive pulmonary disease: doubt some more.Therapeutic advances in chronic disease · 2010Article
- C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik Study.Cephalalgia : an international journal of headache · 2009Article
- C-reactive protein as a predictor of disease in smokers and former smokers: a review.International journal of clinical practice · 2009Review
- Article
- Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study.PloS one · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
C-reactive protein (CRP) has been widely promoted as a strong, independent predictor of cardiovascular events and metabolic syndrome, both in general populations and in patients with clinical cardiovascular disease, and as a causal player in atherothrombosis. However, recent evidence shows that the association of CRP with cardiovascular events is weaker than previously thought, that it may be largely attributed to confounding by established causal risk factors, and that CRP is, therefore, probably not a clinically useful risk predictor. The lack of association of noncoding CRP gene polymorphisms (which determine different baseline CRP values) with coronary events or metabolic syndrome does not support a causal role for CRP, and most of the putatively proatherothrombotic in vitro effects claimed for CRP were caused by contaminants in commercial CRP preparations and not by CRP. Future clinical trials of specific CRP inhibitors now in development could directly test the contribution of CRP to pathogenesis of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.